Erich Hunziker
Since July 2019 Dr. Erich Hunziker is the Chairman of NovImmune.
Erich Hunziker
Since July 2019 Dr. Erich Hunziker is the Chairman of NovImmune.
He is also Chairman of the Board of Directors of BB Biotech AG. He previously served as CFO of Roche from 2001 to 2010. From 1983 to 2001 he held various executive positions at Corange, Boehringer Mannheim and at Diethelm-Keller-Group (DKSH), where he ultimately served as CEO.
In 2013 he was the seed investor to support EngMab AG, which successfully developed a BCMA-bispecific Antibody: EngMab was sold to Celgene in 2016.
Dr. Erich Hunziker is Chairman of Entsia International AG and a co-founder and a member of the Boards of the LamKap Bio group.
Dr. Erich Hunziker earned a Ph.D. in Industrial Engineering from the Swiss Federal Institute of Technology in Zurich.
Holger Blum
Since July 2019 Holger Blum is a Board Member of NovImmune.
Holger Blum
Since July 2019 Holger Blum is a Board Member of NovImmune.
Holger Blum is founding partner of Patinex Management AG, which provides consulting and advisory services for family offices, corporates and banks. More than 20 years ago he started his career as sell-side healthcare analyst at Deutsche Bank and got voted no 1 in European Biotech and Medtech Research in the Institutional Investor Survey in several years.
In 2014 he became partner of BZ Bank and was in charge of private and public healthcare investments. As such he represented the interests of NovImmune`s majority shareholder and was instrumental in the split and divestment of certain NovImmune assets to Sobi.
Holger Blum graduated with an MBA degree from the University of Mannheim, Germany and Western Illinois University in Macomb, USA.
